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Purpose: To compare the Clareon® (Alcon Laboratories, Inc.) intraocular lens 
to theTecnis PCB00® (Johnson & Johnson Inc.) in terms of visual performance, 
refractive outcomes, glistenings occurrence and quality of life outcomes.  
 
Setting: Guy’s and St Thomas’ NHS Foundation Trust, London, England. 
Design: Single-center, single-masked, prospective, randomized, controlled 
trial. 
Methods: 139 patients with bilateral cataracts were randomized to receive 
Clareon® or Tecnis PCB00® IOLs. Visual acuity, refraction, central corneal 
thickness (CCT), endothelial cell loss, contrast sensitivity and mesopic gap 
acuity, evaluation of glistenings and rates of peri- and postoperative 
complications were recorded. Quality-of-life outcomes were measured with the 
EuroQOL 5-dimension questionnaire (EQ-5D) and patient-reported outcome 
measures questionnaire (Cat-PROM5). Optimised A-constants were available 
for PCB00®, but not for Clareon ®. 
 
Results: 71 patients (140 eyes) received Clareon® and 68 patients (134 eyes) 
received PCB00® IOLs. Data were analysed for the first implanted eye. At 12 
months, mean uncorrected distance visual acuity (logarithm of minimum angle 
of resolution [logMAR]) was 0.02+/-0.10 and 0.01+/-0.08 (mean+/-standard 
deviation [SD]; P=0.49; 95% Confidence Interval [CI] -0.02, 0.04) in Clareon® 
and PCB00® IOL groups respectively. Corrected visual acuity was -0.02+/-0.09 
and -0.03+/-0.06 respectively (P=0.45; 95%CI -0.02, 0.04). Increase in CCT 
was 14+/-19 and 16+/-28 micrometers, respectively (P=0.63; 95%CI -10.16, 
6.16). Mean absolute refraction spherical equivalent (SE) error from target 
refraction was 0.41+/-0.28 for Clareon and 0.25+/-0.2 for PCB00 (P=0.002; 
95%CI 0.08, 0.24) groups. Glistenings were minimal (median grade 0), with no 
difference in grades between groups (P=0.2. PROMS improved post-
operatively and were similar in both groups. 
 
Conclusions: There were no differences in visual outcomes between 
Clareon® and PCB00® IOLs. Glistenings were rarely observed in either IOL 
with no difference in grades. There was no difference in peri- or post-op 
complications. Surgeon optimization of the A-constant for new Clareon® IOL 













Any Intraocular lens (IOL) needs to meet fundamental standards, including 
biocompatibility with no induction of inflammation/tissue reaction, excellent 
optical properties and no degradation of shape or optical clarity with time. Whilst 
infrequent, degradations of IOL materials causing visual impairment and 
necessitating lens explantation have been reported.1 
 
Glistenings, which are small, water-filled vacuoles 1-30 micrometers in 
diameter, are one type of material degradation of IOLs.2-4  First reported in the 
mid-1980s,5 they occur in all IOL materials, including poly (methyl methacrylate) 
(PMMA), silicone and hydrophobic acrylic IOLs,6-9 but are more commonly 
associated with hydrophobic acrylic lenses, 6, 9-10  with an incidence of almost 
100% in some older models,11 especially with increasing time.12 The majority 
of clinical studies investigating glistenings show no influence on visual 
outcomes.13-19 However, there are rare single case reports of the need for IOL 
explantation as a result of their occurrence.20-23  For these reasons, IOL 
manufacturers have striven to improve industrial processes to reduce 
glistenings as well as develop ‘glistenings free’ hydrophobic acrylic polymers. 
 
The Clareon® (Alcon Laboratories, Inc.) IOL is a single-piece, aspheric 
monofocal IOL made from a new hydrophobic acrylic polymer (Clareon 
CNA0T0, which has a higher water content (1.5%) than other hydrophobic 
acrylic materials. In laboratory studies this lens has been shown to produce low 
levels of surface haze, roughness and light scatter, minimal glistenings and little 
axial displacement when compared to other hydrophobic acrylic IOLs.24-26 
Whilst these results are encouraging, there are no published clinical studies at 
this time. The aim of this randomized controlled trial was to evaluate visual 
performance, refractive outcomes, patient satisfaction and glistenings 
occurrence at 12 months following implantation of the Clareon® IOL compared 
to the Tecnis PCB00® (Johnson & Johnson Inc.), which has a low rate of 
reported glistenings.27 Glistenings were quantified subjectively using our 
standardized 8-point ordinal scale 19. In addition to standard visual acuity 
testing, we employed an array of computerized vision tests, to measure 
mesopic acuity, functional contrast sensitivity and forward light scatter, 
(Advance Vision and Optometric Tests [AVOT], City Occupational Ltd, London, 
UK).28, 29  Patient reported outcome measures (PROM) and utility values were 




Patients and Methods 
 
The study was a prospective, single-centre (Guy’s and St Thomas’ Hospital 
NHS Foundation Trust (GSTT), London, United Kingdom) randomized 
controlled trial (RCT) (Clinicaltrials.gov registration number NCT02825693), 
approved by West-Midlands Solihull Research Ethics Committee (reference 
17/WM/0414), which adhered to the tenets of the Declaration of Helsinki. 
  
Patients were recruited from the cataract service at GSTT, between February 
and July 2018. Informed consent was obtained by members of the trial team 
(DPSO, NS, VKW, EA, SR, MB) as per the trial protocol. Inclusion and 
exclusion criteria are listed in table 1. Patients were randomized to receive 
either Clareon® or PCB00® IOLs (each receiving the same lens in both eyes) 
using a shuffled, closed envelope system selected by a masked observer 
unrelated to the study. All treatments were delivered by the National Health 
Service, free at the point of care. If a patient failed to attend a follow-up visit, 
they were contacted and offered another appointment. If they failed to attend 




To maintain surgical consistency, femtosecond laser (FL) assisted cataract 
surgery (FLACS) was performed in all eyes using the LenSx platform (Alcon 
Laboratories, Inc.). The FL was used to undertake capsulotomy, lens 
fragmentation and astigmatic keratotomies. Strict criteria for suitability for 
FLACS was followed so that no recruited patients would be excluded from the 
trial (table 1). Astigmatic keratotomies were performed on patients with corneal 
astigmatism greater than 0.8 diopters (D) based on corneal topography. All 
operations were performed under a local anaesthetic (LA) unless clinically 
indicated otherwise. All outcomes’ analysis was undertaken only on the first 
operated eye, except for PROMS data which was collected on bilateral cases. 
No other additional procedures were planned, other than the FL astigmatic 
keratotomies. Phacoemulsification was performed in all eyes using an active-
fluidics torsional phacoemulsification system (Centurion, Alcon Laboratories, 
Inc.). The IOL used for in-the-bag placement was randomized to either 
Clareon® (Alcon Laboratories, Inc.) or Tecnis® PCB00 (Johnson & Johnson 
Inc.).  Operations were performed by six surgeons who had completed at least 
30 FLACS procedures (NS, EA, DPSO, VW, MB, SR) before study 
commencement. 
 
Characteristics of the Clareon® or PCB00® IOLs 
 
Both Clareon® and PCB00® incorporate an aspheric anterior surface 32 and 
are made from hydrophobic acrylic polymers developed to minimize the 
glistenings formation. The lenses have several similar characteristics, but are 
composed of differing acrylic polymers, with the Clareon® IOL employing a blue 
light filtering chromophore (table 2). 
 
Data Collection  
 
Outcomes reported in this study are shown in table 3. Data collection occurred 
preoperatively, on the day of surgery and at 1, 6 and 12-months postoperatively 
(table 3). Visual acuity and other assessments (corneal topography, specular 
microscopy, etc.) were conducted by trained technicians, masked to the 
participants’ treatment arm. Participants were masked to their treatment arm 
but because of the nature of the intervention, neither the surgeon nor the 
surgical team could be masked. Visual acuities (uncorrected distance visual 
  
acuity (UDVA), corrected distance visual acuity (CDVA)) were measured with 
a standard Early Treatment Diabetic Retinopathy Study (ETDRS) backlit chart 
at 4 meters (m) (Precision Vision, Illinois, USA). Participants’ refractive errors 
were measured using an auto-refractor (RK-510A, Nidek Co. Ltd.) and checked 
subjectively by a single investigator (NS). Biometry was performed using partial 
coherence interferometry (IOL Master 500, Carl Zeiss Meditec AG). Corneal 
topography and Central Corneal Thickness (CCT) were determined using a 
Scheimpflug device (Pentacam HD, Oculus Optikgeräte GmbH). Macular 
spectral-domain optical coherence tomography (OCT) was performed with a 
modular ophthalmic imaging platform (Spectralis, Heidelberg Engineering 
GmbH) at 1 month and then as per clinical need. The endothelial cell count 
(ECC) was measured with a specular microscope (EM-3000, Tomey GmbH 
[Europe], Germany) preoperatively and then at 1 month. Visual comorbidities 
and risk factors for complications of cataract surgery were recorded 
prospectively. The risks for posterior capsule rupture were calculated for 
patients using a composite risk calculation system.33  
 
Advanced Vision and Optometric Tests (AVOT) 
 
Advanced Vision and Optometric Tests (AVOT, City Occupational Ltd, London, 
UK, (http://www.city.ac.uk/avot)) were performed under background mesopic 
conditions (ambient illuminance on the display surface <0.3 lux, a background 
display screen luminance of 1Cd m-2).  The following specific tests were used: 
i) Gap acuity using a Landolt ring for positive (target lighter than the 
background) and negative contrast (a darker target on a lighter background) at 
a viewing distance of 3m.  
ii) Functional contrast sensitivity (FCS) using a Landolt ring (as for gap acuity) 
with a 3’ gap for both positive (target lighter than the background) and negative 
contrast (a darker target on a lighter background) at a viewing distance of 3m. 
A gap size of 3’ (Landolt ring size 15’) was employed to avoid eyestrain and to 
minimize the effects of micro-fluctuations of accommodation.34 
iii) Forward light scatter utilizing a flicker cancellation method35-36 with a single 
ring of fixed size designed to produce specified luminance levels in the plane 
of the pupil from a viewing distance of 70cm. Both ‘low threshold’ and ‘high 
threshold’ were evaluated, with the software calculating the straylight 
parameter and integrated straylight parameter. 
 
 
Digital Imaging and Objective Quantification of Glistenings 
 
The methodology used for grading glistenings has been published previously.19 
Following pupillary mydriasis, with tropicamide 1% and phenylephrine 2.5%, 
central vertical slit images of 10.0 millimeters (mm) by 2.0mm at an angle of 40 
degrees and 16x objective magnification of the IOLs were taken with a 5MP 
digital camera (Topcon DC-4, Topcon, Tokyo, Japan) mounted on an SL 
(Topcon SL-701, Topcon). We used strictly controlled ambient and display 
screen equipment illumination as per the published protocol (ISO of 800, a 
shutter speed of 1/30 second, sharpness of ‘+32’ (default), denoising of ‘0’ 
(default), contrast ‘of 50’ (default) and ‘auto-brightness’ setting at “off’’), with the 
ambient illuminance on not exceeding 0.3lux 20. 
  
 
The best of five colour digital images from each study eye was selected on the 
basis of its image clarity for analysis and was processed by fitting the pupil, 
identifying its centre and over-laying a 3.0mm by 1.0mm grid divided into 
1.0mm2 areas. Three ophthalmologists (NS, JO and DPSO) assessed and 
graded the images independently within the 3 defined 1.0mm2 grid squares by 
counting the number of glistenings they could identify, while disregarding 
artifacts such as anterior or posterior surface particulates such as pigment, IOL 
scratches and scuff marks, posterior capsule irregularities and vitreous floaters. 
To reduce assessor bias, image strips were randomized and presented to the 
graders for evaluation in PowerPoint (Microsoft Corporation, WA, USA) by a 
fellow researcher not involved in grading (CH). 
 
Grades of glistenings density were assigned to each 1.0mm2 area according to 
an 8–point ordinal scale based on increments of 10 glistenings per mm2 from 
zero (grade 0) to more than 60 (grade 7). In addition to our system 19, glistening 
density was also graded, by the three independent graders, using the 
previously published Miyata grading scale.37 
 
Patient Reported Outcomes and Quality of Life Questionnaires 
 
PROMs were assessed with the Cat-PROM5 tool consisting of 5 questions that 
provide a Rasch calibrated psychometrically robust measure, specifically 
designed for cataract surgery, in which a higher score indicates greater visual 
disability.30-31 Quality of life outcomes were assessed using the EuroQOL EQ-
5D questionnaire, consisting of 2 components: 5 questions about 5 dimensions 
of health-related quality of life (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression), which were scored as 1, 2, or 3 (1 
meaning no problems and 3 meaning extreme problems). The 5 responses 
were then weighted and combined to create a summary index with values 0 to 
1, where 1 indicates no problems. The visual analogue scale was a continuous 
scale anchored by best imaginable and worst imaginable health, with values 
ranging from 0 to 100 (where 100 indicates best possible health). The EQ-5D 
was chosen because it is well recognized by public bodies (such as the National 
Institute for Health and Care Excellence in the UK) for comparative health 





Results were analysed as per intention to treat. Continuous data were reported 
using means +/- SDs if the data appeared Gaussian. Binary data were reported 
as frequencies and percentages and evaluated with the Fisher exact test. 
Student t tests were used for parametric data with non-parametric equivalent 
tests used when data failed the parametric test assumptions. All statistical tests 
were 2-sided with a significance level of 5% (α=0.05). Intraoperative or 
postoperative adverse events were defined as any event that involved 
unintentional trauma to an ocular structure, requiring additional treatment or 
having a negative effect on participants’ eyesight. The EQ-5D index scores 
were calculated using the visual analogue score method calibrated for the UK. 
  
The Rasch-calibrated Cat-PROM5 scores (logits) were calculated from the 
questionnaire responses in accordance with the developer’s instructions 30-31. 
The UDVA at 12 months was designated as the primary outcome with peri-
operative and postoperative complications, incidence and density of 
glistenings, refraction, corneal thickness and the results of AVOT tests 
(mesopic gap acuity at positive and negative contrast, functional contrast 
sensitivity at positive and negative contrast, and forward light scatter expressed 
through the straylight and integrated straylight parameter) all as secondary 





Subjects and Patient Demographics 
 
One hundred and forty-five patients were recruited.  Five withdrew before the 
surgery date and 140 continued with the trial. 
 
Seventy-one patients (142 eyes) were randomized to the Clareon® arm with 
140 eyes treated. Two patients decided against second eye surgery: one had 
unilateral surgery and withdrew after 1-month; the other decided against 
second eye surgery but continued with first-eye follow-ups until study end. 
Therefore 69 patients were available for analysis at 6 months. One patient (both 
eyes) missed their 12-month follow up, so that 68 Patients were available for 
analysis at 12-months.  
 
Sixty-eight patients (136 eyes) were randomized to the PCB00® group. Of 
these, 134 eyes (68 patients) were treated, with 1 having only one eye treated 
and withdrawing after 1-month, 1 not having second-eye surgery but attending 
follow-ups until study end and 1 withdrawing after 6-months.  One patient had 
bilateral surgery but due to health problems, missed 1- and 6-month follow-up 
but attended for 12-month follow up. Therefore at 6 months, 67 patients 
attended for follow up and at 12 months 66 patients attended. Two patients did 
not receive the PCB00 IOL as intended due to surgical complications but 
received the Alcon MA60AC sulcus IOL. They were considered in the visual 
outcomes’ results analysis and for glistenings analysis at 12-months on “an 
intention-to-treat” basis. 
 
The patient demographics and full baseline data are shown in table 4, with no 
significant differences between the two treatment arms.  
 
Surgical Procedures and Peri-operative Events 
 
All surgeries except 4 second-eye procedures (2 per group) were undertaken 
under LA. One patient (PCB00® group) had to have surgery in two stages due 
to feeling ‘dizzy’ after FL procedure and surgery was completed the following 
day under general anaesthetic. All patients were able to receive the FL 
treatment successfully as planned. Perioperative events and complications are 







Post-operative visual, refractive, EEC, CCT and PROMS results are shown in 
table 6. There were no differences in UDVA at 12 months, change in CCT at 
12 months, ECC loss at 1-month, residual refractive cylinder at 12 months and 
changes in PROM indices [CatPROM scores, EQ5-3D index scores and visual 
analogue scale (VAS)] at 12 months. Mean absolute refraction spherical 
equivalent (SE) error from target refraction at 12 months was 0.41+/-0.28 for 
Clareon and 0.25+/-0.2 for PCB00 (P=0.002; 95%CI 0.08, 0.24) groups, with 
consequently  mean manifest refraction SE error greater (P<0.001) and SE 
refraction within +/- 0.50 D reduced in the Clareon® group at 12 months 
(P<0.012) (table 6, figures 1 and 2).  
 
Rates of post-operative adverse events are documented in table 7. There were 
no differences in rates of posterior capsular opacification (PCO), YAG 
capsulotomies, negative dysphotopsias or cystoid macular oedema (CMO) 
between treatment groups (table 7). 
 
Advance Vision and Optometric Tests (AVOT) 
 
There were no differences between the groups in terms of mesopic gap acuity 
at either positive or negative contrast, functional contrast sensitivity at either 
positive of negative contrast or the forward light scatter as expressed with either 
the straylight parameter or the integrated straylight parameter (table 8).  In 
general, the raw data were skewed, and so non-parametric tests were used, 




There was no statistically significant difference in the median glistenings grades 
for all graders between the Clareon® and PCB00® lenses (P=0.2; Mann-
Whitney test) when we used the grading scale previously described by our 
group.19 The median grade for the two IOL groups was 0 (<1 glistening/mm2). 
Four Clareon® IOLs developed grade 1 glistenings (between 1-10 glistenings 
per mm2) whereas only 1 PCB00® IOL was similarly affected.19 In two of these 
4 Clareon® IOLs we found small surface scratch marks from the injector 
plunger (Monarch, Alcon Laboratories, Inc.). In no cases were median 
glistening grades >10mm2 seen in any IOL in either group. 
 





This is the first study to investigate the performance of the Clareon® IOL using 
an RCT. At 12 months, visual results were excellent, in terms of LogMar UCVA 
  
and CDVA, contrast sensitivity and forward scatter, with no differences 
compared to the PCB00® IOL (tables 6 and 8; figures 1 and 2). There was, 
however, a significant difference between IOLs in mean manifest refraction SE 
error, mean absolute SE refractive error from target refraction at 12 months 
(table 6).  The proportion of patients with SE refraction within +/-0.50 D was 
significantly higher in the PCB00® lens group (table 6, figures 1 and 2). We 
believe this is due to the use of the non-optimized, A-constant for the new 
Clareon® IOL (119.1)  compared to the Tecnis® IOL which has been in the 
market longer and has well established optimized and surgeon-personalized A-
constants which were applied during this study. This difference in methodology 
appears to have resulted in the slight hyperopic overcorrection found. Given 
the similarity of the pre-operative characteristics of the IOLs investigated (table 
2), the standardization of surgeries and post-operative assessments in this trial 
and the very similar variances of the refractive results between the two IOL 
groups at 12 months (table 6), we believe that a simple adjustment/surgeon 
optimization of the A-constant would result in similar (non-statistically 
significant) refractive outcomes and optimize refractive outcomes for the 
Clareon® lens. 
 
The Clareon® IOL is manufactured using a new hydrophobic acrylic material 
(Clareon CNA0T0), developed to provide greater resistance to glistenings 
formation and improve lens clarity characteristics post-surgery. This study has 
demonstrated that there were typically no detectable glistenings at 12 months, 
with a median grade of 0 (<1 glistening per mm2) for the Clareon IOL as well as 
the PCB00®. However, some of the IOLs in our study had a small number of 
glistenings. Although there are no strict criteria to state how many glistenings 
are allowed for any particular IOL to be labeled “glistenings-free”, historically 
experts in the field have used the cut off to be up to 50 glistenings per mm2, 
probably based on a historical grading scale.37 It is of note that none of the IOLs 
in either treatment arm of our study had more than 10 glistenings mm2 (Grade 
2 on the St Thomas’ scale).19 Interestingly, in 2 of the only 4 Clareon® IOLs in 
which we detected grade 1 glistenings, we found minimal scratch marks from 
the injector plunger on the IOL surface, which may have been a contributing 
factor. We expect that such scratches would not have occurred if we had used 
the ‘AutonoMe’ (Alcon Laboratories, Inc.) platform for IOL delivery.  Further 
studies may clarify if automated IOL delivery systems could reduce scratches 
and perhaps the occurrence of associated glistenings. 
 
The relatively high water content of the Clareon  CNA0T0 material (1.5%) 24 
may explain why it is can be classified as “glistenings-free” 37 as the amount of 
fluid in hydrophobic acrylic materials has previously been shown to be 
negatively  correlated with the occurrence of glistenings.42 It is important to note 
that one limitation of this study is the 12-month follow up; a longer follow up is 
needed when examining the development of glistenings, ideally over 10 years. 
Cataract surgery is being undertaken in increasingly younger patients. Indeed, 
in the case of refractive lens exchange, this is often at the onset of presbyopia 
and this taken together with increasing life expectancy, means that modern 
IOLs need to maintain optical clarity for several decades. At present, long-term 
data regarding IOL material clarity for periods greater than 10 years is lacking. 
Even minimal amounts of IOL material degradations, such as glistenings, noted 
  
in the early/medium post-operative period should be taken seriously and further 
longer-term follow-up research is required. 
 
One difference between the IOLs in this study is that Clareon® contains a blue 
light-filtering chromophore and the PCB00® does not. There has been 
controversy concerning the use of blue light filters in IOLs. At present there is 
no strong evidence from clinical studies to either confirm or dismiss any 
theoretical benefits of blue-light filtering IOLs for macular protection.39  Blue-
light filtering IOLs have previously been found to have little effect on visual 
acuity or on contrast vision. 40, 41. It is of note that in this study, where we 
undertook both positive and negative contrast acuity testing under mesopic 
conditions, we found no differences between IOL groups (table 8).  
 
In terms of postoperative adverse events, all levels of PCO (including small 
peripheral non-visually significant PCO) were recorded on slit-lamp 
examination by one observer (NS) and was confirmed by the consensus of two 
graders (DO’B, NS) who carefully analysed digital images of these patients. At 
12 months, both groups showed a low rate of Nd:Yag laser posterior 
capsulotomy with no differences between treatment arms (table 7). However, it 
would be interesting to see how the PCO develops over a longer follow-up time. 
 
Both Clareon® and PCB00® are described broadly as ‘square-edge-design’ 
IOLs. Recent research has shown that edges of such IOLs vary but are 
smoother than designs from 10 years ago.43  Of 9 hydrophobic acrylic IOLs in 
one study, Clareon® had the lowest edge thickness at 167.2 microns 43 while 
another found that the IOL designs with optic edge curvature and full functional 
optics, such as Clareon®, demonstrated the lowest level of glare-type photic 
phenomena.44 The Clareon® IOL features a full 6.0 mm optic and a modified 
edge profile where the center point of the edge radius lies posterior to the 
optical plane, designed to reduce dysphototopsia. The Tecnis PCB00® 
employs optic bodies that incorporate additional peripheral non-imaging 
components, thus reducing the functional optic diameter. In laboratory testing 
with non-sequential ray-tracing evaluations, the Clareon® IOL has been shown 
to produce the main image beam without any secondary glare components 
whereas the Tecnis ZCB00® (an IOL very similar to the PCB00®) has shown 
secondary glare components.44 In this study, we had only one patient in each 
group with negative dysphotopsias that resolved at 12 months follow up, 
probably due to neuroadaptation (table 7). 
 
As expected, all PROMS improved very significantly in both groups post 
operatively. All the indices remained stable and were not significantly different 
between the groups from 6 months to 12 months (table 6). 
In summary, we found no significant difference in visual outcomes between 
Clareon® and PCB00® lenses. Glistenings were rarely observed in both IOLs, 
with no difference in median grades on two grading systems. There was no 
significant difference in peri- or post-operative complications. PROMs improved 
to a similar degree in both groups. As with any new lens, Clareon® requires 
optimization/surgeon personalization of the manufacturer-proposed A-constant 
to improve predicted refractive outcomes. 
  
 
WHAT WAS KNOWN 
• Hydrophobic acrylic IOLs, especially with AcrySof material, have been 
found to have a propensity to develop glistenings following implantation. 
• Previous studies differ in their grading/evaluation of IOL glistenings in 
vivo and few studies have found association between glistenings and 
visual function 
• New IOL designs with new materials, of which Clareon® is one, have 
been developed for greater clarity and resistance to glistenings 
formation. 
 
WHAT THIS PAPER ADDS 
• In this trial, both Clareon® and PCB00® IOL rarely develop glistenings 
with up to 12-month follow-up and when they do occur it is at very low 
levels. 
• Visual and quality of life outcomes with Clareon® and PCB00® IOL are 
comparable. 
• The new Clareon® IOL may require optimization/surgeon 
personalization of the manufacturer-proposed A-constant to improve 
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Table 1.  Inclusion and exclusion criteria for enrolment in the trial 
 Inclusion criteria Exclusion criteria 
1) Bilateral cataracts requiring surgical 
intervention 
2) Good visual potential in both eyes 
3) Age18-100 years 
4) Ability to understand informed consent and 
the objectives of the trial 
5) Not pregnant, not breast feeding 
6) No previous eye surgery 
7) Corneal astigmatism less than 1.5D in both 
eyes 
 
Any patient with co-existing ocular condition 
that might reduce visual acuity and hence 
confound the results such as: 
1) age-related macular degeneration 
2) glaucoma 
3) previous retinal vascular disorders 
4) previous retinal detachment or tear 
5) any neuro-ophthalmological condition 
6) any inherited retinal disorder or pathology 
7) previous strabismus surgery or record of 
amblyopia 
8) previous TIA, CVA or other vaso-occlusive 
disease 
9) already enrolled in another study 
10) Exclusion criteria related to clinical 
contraindications for FLACS, such as: 
1. Significant corneal opacities 
2. Small pupils following 
pharmacological dilation 
3. Patients unable to lie sufficiently flat to 

































Table 2. Characteristics of the two intraocular lenses under 
investigation. 
Lens Type Clareon PCB00 
Optic diameter (mm) 6 6 (functional diameter 4.9) 
Overall length (mm) 13 13 
Material Hydrophobic acrylic Hydrophobic acrylic 
Design Biconvex 
Anterior aspheric surface; 
Modified square (anterior) 
precision edge curvature 
Biconvex 
Anterior aspheric surface; 
Square optic edge: Protec® 
Frosted, continuous 360 
Posterior square edge 
Haptics Stableforce® ‘C’ style offset from optic 
Refractive index 1.55 1.47 











Table 3. Schedule for data collection in this study 
 Pre-op 1 months 6 months 12 months 
Patient information and informed 
consent 
X    
Visual acuity testing, refraction, slit 










AVOT tests  X X X 
Dilation of pupils (g.tropicamide 1% 
and g.phenylephrine 2.5%) 
X X X X 
Intraocular lens photographs  X X X 
Dilated fundal examination X X X X 
Biometry X  X  
OCT macula X X   
Endothelial cell count X X   
EQ5D3L and catPROM5 
questionnaires 
X X X X 





















Table 4. Baseline Characteristics of the two treatment groups.  (All 





P value (95% CI) 
Gender 
(male/female) 
19/52 26/42 n/a 
Right eye/left eye 38/33 42/26 n/a 
Mean age (range) 68.9 +/- 10.2 (47, 
90) 
68.4 +/- 9.3 (37, 
81) 
0.76 (-2.78, 3.78) 
Mean pre-op CDVA 
(LogMAR) 
0.43 +/- 0.45 0.41 +/- 0.36 
 
0.77 (-0.12, 0.16) 
Mean SE refractive 
error (D) 
0.02 +/- 1.7 -0.25 +/- 0.88 0.25 (-0.19, 0.73) 
Mean AL (mm) 23.54 +/- 0.75 23.78 +/- 0.88 0.09 (-0.51, 0.03) 
Mean ACD (mm) 3.27 +/- 0.36 3.3 +/- 0.35 0.62 (-0.15, 0.09) 
Mean target 
refraction (D) 
-0.11 +/- 0.13 -0.09 +/- 0.12 0.35 (-0.06, 0.02) 
Mean IOP (mmHg) 12 +/- 4 13 +/- 4.4 0.16 (-2.41, 0.41) 
Mean CCT 
(microns) 




2540 +/- 297 2473 +/- 297 0.19 (-32.65, 
166.65) 
Mean predicted 
odds ratio of PCR for 
all treated eyes 33 
1.75 +/- 1.99 
(n=140) 
1.70 +/- 1.01 
(n=134) 
0.8 (-0.33, 0.43) 
Mean CAT-PROM5 
calibrated score 
0.95 +/- 2.31 0.96 +/- 2.18 0.98 (-0.76, 0.74) 
Mean EQ-5D-3L 
index score 
80.69 +/- 15.85 81.90 +/- 15.40 0.65 (-6.46, 4.04) 
Mean EQ-5D visual 
analogue scale 
score 



















Table 5. Peri-operative events 
 Number of events P value 
 Clareon PCB00  
Iris trauma/prolapse 1 1 1 
Retained cortical 
matter 
1 1 1 
Angle trauma 0 1 0.49 
Stuck haptics 0 1 0.49 
Mal-positioned 
haptics 
0 1 0.49 
Posterior capsule 
rupture 
0 1 0.49 













































P value (95% CI) 
Mean UDVA 
(LogMAR) 
0.02 +/- 0.1 0.01 +/- 0.08 
 
0.49 (-0.02, 0.04) 
Mean change in CCT 
(pre-op vs 12 month) 
14 +/- 19 
 
16 +/- 28 0.63(-10.16, 6.16) 
Mean ECC difference 
(pre-op vs 1 month) 
(cells/mm2) 




8.4 +/- 6.3 
 
10.2 +/- 10.1 0.22 (-4.67, 1.07) 
Mean manifest 
refraction SE error 
(D) 12 months 
0.23 +/- 0.40 0.02 +/- 0.3 0.001 (0.01, 0.33) 
Mean absolute SE 
refractive error from 
target refraction (D) 
12 months 
0.41 +/- 0.28 0.25 +/- 0.20 0.002 (0.08, 0.24) 
Residual refractive 
cylinder (D) 12 month 
-0.9+/-0.53 -0.74 +/- 0.47 0.062(-0.33, 0.01) 
SE refraction within 
+/- 0.50 D* 12 months 
78% (53/68) 94% (62/66) 0.012 
SE refraction within 
+/- 1.00 D* 12 months 
99% (67/68) 100% (66/66) 1.0 
Mean change in CAT-
PROM calibrated 
score 
(pre-op vs 6 months) 
-8.16 +/- 3.02 -7.67 +/- 3.27 0.35 (-1.56, 0.56) 
Mean change in CAT-
PROM calibrated 
score 
(pre-op vs 12 
months) 
-7.41 +/- 3.03 -7.56 +/- 2.76 0.761(-0.82, 1.12) 
Mean Change in EQ-
5D-3L index score 
(pre-op vs 6 months) 
0.03 +/- 0.12 0.06 +/- 0.15 0.194(-0.08, 0.02) 
Mean Change in EQ-
5D-3L index score 
(pre-op vs 12m 
months) 
-0.02 +/- 0.12 -0.02 +/- 0.15 1 (-0.05, 0.05) 
Mean change in EQ-
5D visual analogue 
scale (pre-op vs 6 
months) 
11.29 +/- 18.5 10.12 +/- 16.86 0.7 (-4.78, 7.12) 
Mean change in EQ-
5D visual analogue 
scale (pre-op vs 12 
months) 
6.82 +/- 16.76 5.89 +/- 15.22 0.73 (-4.45, 6.31) 









Table 7. Post-operative adverse events 














2 (1.5) 2(1.5) 1 
Negative 
dysphotopsias at 
6 months  













































Table 8. Advance Vision and Optometric Test results (AVOT) 
Vision test Clareon  
N=68 






























88.05 (50.62, 99.47) 86.56 (48.03, 98.66) 0.454 
Straylight 
parameter 















Fig 2. Visual and refractive outcomes at 12 months - PCB00 group (n=66).  
 
